- Home
- ENOV
ENOV
Enovis Corporation
as 12-17-2024 4:00pm EST
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 2.7B | IPO Year: | 2008 |
| Target Price: | $67.44 | AVG Volume (30 days): | 539.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.27 - $65.03 | Next Earning Date: | 11-06-2024 |
| Revenue: | $2,001,668,000 | Revenue Growth: | 20.52% |
| Revenue Growth (this year): | 25.59% | Revenue Growth (next year): | 5.97% |
Latest Enovis Corporation News
ENOV Breaking Stock News: Dive into ENOV Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
ENOV: Lowering target price to $37.00
Argus Research
15 days ago
ENOV: Raising target price to $39.00
Argus Research
22 days ago
ENOV: Raising target price to $38.00
GlobeNewswire
a month ago
Enovis to Participate in Upcoming Investor Conferences
Argus Research
a month ago
ENOV: Raising target price to $38.00
Zacks
a month ago
Enovis (ENOV) Upgraded to Buy: Here's Why
Zacks
a month ago
Wall Street Analysts Predict a 38.95% Upside in Enovis (ENOV): Here's What You Should Know
GuruFocus.com
a month ago
Enovis Corp (ENOV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Compare ENOV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENOV Enovis Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.